MedTrace Logo

Effects of Salbutamol in Athletes and Implications for Screening and Sports

NCT07037511 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 64

Last updated 2026-03-13

No results posted yet for this study

Summary

β2-Agonists, commonly used to treat asthma, have also been used by athletes to enhance performance, leading to their ban by the International Olympic Committee in 1972. Research has shown non-asthmatics receive no benefit from these drugs at therapeutic dosages; however, many elite athletes still use them, and asthmatic athletes often win more Olympic medals. In some non-asthmatics, β2-agonists may improve breathing limitations during high intensity exercise, which may improve performance. Therefore, we aim to examine if there is a select group of non-asthmatic individuals who experience breathing limitations that may receive benefit from β2-agonists.

Conditions

  • Asthma
  • Healthy
  • Effect of Drug

Interventions

DRUG

Salbutamol

Meter-dose inhaler of salbutamol performed using large-volume spacer

DRUG

Placebo

Meter-dose inhaler of placebo performed using large-volume spacer

Sponsors & Collaborators

  • University of British Columbia

    lead OTHER

Principal Investigators

  • Jordan A Guenette, PhD · University of British Columbia

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-10-30
Primary Completion
2029-12-31
Completion
2030-12-31

Countries

  • Canada

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07037511 on ClinicalTrials.gov